CN116745310A - 化合物及其在治疗速激肽受体介导的病症中的用途 - Google Patents

化合物及其在治疗速激肽受体介导的病症中的用途 Download PDF

Info

Publication number
CN116745310A
CN116745310A CN202180089751.3A CN202180089751A CN116745310A CN 116745310 A CN116745310 A CN 116745310A CN 202180089751 A CN202180089751 A CN 202180089751A CN 116745310 A CN116745310 A CN 116745310A
Authority
CN
China
Prior art keywords
nk2r
agonist
amino acids
less
mod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180089751.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·B·F·古斯塔夫松
J·马德森
O·穆尔瓦德
W·F·J·霍根多夫
J·B·汉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Ebak Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ebak Biotechnology Co ltd filed Critical Ebak Biotechnology Co ltd
Publication of CN116745310A publication Critical patent/CN116745310A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180089751.3A 2020-11-09 2021-11-09 化合物及其在治疗速激肽受体介导的病症中的用途 Pending CN116745310A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20206509 2020-11-09
EP20206509.0 2020-11-09
PCT/EP2021/081057 WO2022096736A1 (en) 2020-11-09 2021-11-09 Compounds and their use in treatment of tachykinin receptor mediated disorders

Publications (1)

Publication Number Publication Date
CN116745310A true CN116745310A (zh) 2023-09-12

Family

ID=73198203

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180089751.3A Pending CN116745310A (zh) 2020-11-09 2021-11-09 化合物及其在治疗速激肽受体介导的病症中的用途

Country Status (13)

Country Link
US (1) US20230406883A1 (https=)
EP (1) EP4240749A1 (https=)
JP (1) JP2023551122A (https=)
KR (1) KR20230106616A (https=)
CN (1) CN116745310A (https=)
AU (1) AU2021374843A1 (https=)
CA (1) CA3197916A1 (https=)
CL (1) CL2023001325A1 (https=)
CO (1) CO2023007404A2 (https=)
IL (1) IL302745A (https=)
MX (1) MX2023005408A (https=)
PE (1) PE20231952A1 (https=)
WO (1) WO2022096736A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117384258A (zh) * 2023-10-12 2024-01-12 湖南中晟全肽生化有限公司 一种神经激肽受体2（nk2r）激动剂及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
WO2023118263A1 (en) * 2021-12-21 2023-06-29 Embark Biotech Aps Agonists for treatment of eating disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2427475T3 (pl) * 2009-05-08 2021-07-19 Techfields Biochem Co., Ltd. Kompozycje proleku o wysokim przenikaniu peptydów i związków powiązanych z peptydami
CN105722526B (zh) * 2013-11-15 2020-12-08 诺和诺德股份有限公司 选择性pyy化合物及其用途
TWI694082B (zh) * 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
WO2019059963A1 (en) * 2017-09-21 2019-03-28 Dignify Therapeutics, Llc COMPOSITIONS FOR INDUCING MICTION AND DEFECATION
US11633459B2 (en) * 2018-05-04 2023-04-25 Novo Nordisk A/S GIP derivatives and uses thereof
MX2022004566A (es) * 2019-10-17 2022-07-21 Univ Copenhagen Agonista del receptor de taquiquinina 2 (tacr2).

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117384258A (zh) * 2023-10-12 2024-01-12 湖南中晟全肽生化有限公司 一种神经激肽受体2（nk2r）激动剂及其应用
CN117384258B (zh) * 2023-10-12 2024-07-26 湖南中晟全肽生物科技股份有限公司 一种神经激肽受体2（nk2r）激动剂及其应用

Also Published As

Publication number Publication date
CO2023007404A2 (es) 2023-07-10
EP4240749A1 (en) 2023-09-13
WO2022096736A1 (en) 2022-05-12
MX2023005408A (es) 2023-07-25
KR20230106616A (ko) 2023-07-13
IL302745A (en) 2023-07-01
US20230406883A1 (en) 2023-12-21
AU2021374843A9 (en) 2024-08-08
JP2023551122A (ja) 2023-12-07
CA3197916A1 (en) 2022-05-12
AU2021374843A1 (en) 2023-06-08
PE20231952A1 (es) 2023-12-06
CL2023001325A1 (es) 2023-12-15

Similar Documents

Publication Publication Date Title
KR102351313B1 (ko) Gip/glp1 공효능제 화합물
CN116745310A (zh) 化合物及其在治疗速激肽受体介导的病症中的用途
KR102440323B1 (ko) 인크레틴 유사체 및 그의 용도
CN100540565C (zh) 修饰的Exendins及其应用
JP6858174B2 (ja) インターロイキン２３受容体のペプチド阻害剤、および炎症性疾患を処置するためのそれらの使用
CN101389648B (zh) 肽胃泌酸调节素衍生物
JP6387008B2 (ja) インスリンアナローグダイマー
CN107206254A (zh) 白细胞介素‑23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
JP2001527507A (ja) 改良された環状ｃｒｆ拮抗剤
US11572399B2 (en) Long-acting GIP peptide analogues
EP1807099A2 (en) Y2 selective receptor agonists for therapeutic interventions
AU2005224027B2 (en) Y2/Y4 selective receptor agonists for therapeutic interventions
CN118843638A (zh) Crf2受体激动剂及其在治疗中的用途
ZA200607680B (en) Y2 selective receptor agonists for therapeutic interventions
JP2002502381A (ja) 環状ｃｒｆアンタゴニストペプチド
US20240270821A1 (en) Gip/glp1/gcg tri-receptor agonists and uses thereof
CN102076353A (zh) 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽
Laimou et al. Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: enhanced enzymatic stability and biological properties
JP2004002331A (ja) 肝臓癌の治療
EA049082B1 (ru) Соединения и их применение для лечения нарушений, опосредованных тахикининовым рецептором
Kutina et al. Synthesis of new vasotocin analogues: effects on renal water and ion excretion in rats
Mihaylova et al. IN SILICO SCREENING AND IN VIVO EVALUATION OF POTENTIAL ANALGESIC EFFECT OF NEW NEUROTENSIN (NT8-13) PEPTIDE MIMETICS

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Copenhagen, Denmark

Applicant after: Novo Nordisk Research Center Grad Sachs LLC

Address before: Copenhagen, Denmark

Applicant before: Ebak Biotechnology Co.,Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20231123

Address after: Denmark bagsvaerd

Applicant after: NOVO NORDISK A/S

Address before: Copenhagen, Denmark

Applicant before: Novo Nordisk Research Center Grad Sachs LLC